Stock AnalizHenry Schein Inc. HSIC
Medical Specialities · IPO 1995 · data as of November 13, 2026
Henry Schein Inc. (HSIC) is a healthcare company listed in the US with a market value of about $9.5B. In the twelve months to September 26, 2026 it had revenue of $13.7B and net income of $421M, a net margin of 3.1%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is future growth (0/5).
Key numbers: a P/E of 23.6, a price to free cash flow of 17.0, 5-year revenue growth of 5% a year, a 5-year average ROIC of 10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 10% below the current price.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Profitable 5 years in a row
- Positive free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
- Stock-based pay below 5% of revenue
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.7B | $13.2B | $12.7B | $12.3B | $12.6B | $12.4B | $10.1B | $10.0B | $13.2B | $12.5B | $11.6B |
| Net income | $421M | $398M | $390M | $416M | $538M | $631M | $404M | $695M | $536M | $406M | $507M |
| Free cash flow | $559M | $573M | $700M | $353M | $506M | $631M | $550M | $578M | $613M | $483M | $572M |
| EPS (diluted) | $3.65 | $3.27 | $3.05 | $3.16 | $3.91 | $4.45 | $2.82 | $4.65 | $3.49 | $2.57 | $3.10 |
| Net margin | 3.1% | 3.0% | 3.1% | 3.4% | 4.2% | 5.1% | 4.0% | 7.0% | 4.1% | 3.3% | 4.4% |
| ROIC | — | 7.5% | 7.5% | 7.7% | 11.6% | 14.0% | 10.2% | 14.1% | 9.8% | 9.1% | 15.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $96.60, 12% above the current price; targets range from $64.00 to $110.00; the consensus rating is “Buy”; expected EPS is $5.53 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Henry Schein’s P/E ratio?
About 23.6, based on the last twelve months of diluted earnings per share (forward P/E about 14.8).
Is Henry Schein stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 10% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Henry Schein pay a dividend?
Not currently.
Is Henry Schein a good stock to buy?
We do not give buy or sell advice. Henry Schein scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.